pirfenidone has been researched along with Dermatomyositis, Adult Type in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, PK; Tseng, CW; Wang, KL; Yen, TH | 1 |
| Chen, S; Chen, Z; Gu, L; Guo, L; Li, T; Sun, F; Tan, X; Wang, X; Ye, S | 1 |
2 other study(ies) available for pirfenidone and Dermatomyositis, Adult Type
| Article | Year |
|---|---|
Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report.
Topics: Autoantibodies; Dermatomyositis; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Piperidines; Pyridones; Pyrimidines; Rituximab | 2021 |
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatomyositis; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Pyridones; Retrospective Studies; Treatment Outcome | 2016 |